Collegium Pharmaceutical Inc (COLL)
30.40
+0.40
(+1.33%)
USD |
NASDAQ |
Nov 21, 16:00
30.40
0.00 (0.00%)
After-Hours: 20:00
Collegium Pharmaceutical Enterprise Value: 1.715B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 1.715B |
| November 19, 2024 | 1.707B |
| November 18, 2024 | 1.690B |
| November 15, 2024 | 1.701B |
| November 14, 2024 | 1.723B |
| November 13, 2024 | 1.721B |
| November 12, 2024 | 1.760B |
| November 11, 2024 | 1.785B |
| November 08, 2024 | 1.784B |
| November 07, 2024 | 1.867B |
| November 06, 2024 | 1.860B |
| November 05, 2024 | 1.825B |
| November 04, 2024 | 1.802B |
| November 01, 2024 | 1.826B |
| October 31, 2024 | 1.848B |
| October 30, 2024 | 1.865B |
| October 29, 2024 | 1.883B |
| October 28, 2024 | 1.879B |
| October 25, 2024 | 1.866B |
| October 24, 2024 | 1.853B |
| October 23, 2024 | 1.904B |
| October 22, 2024 | 1.914B |
| October 21, 2024 | 1.922B |
| October 18, 2024 | 1.986B |
| October 17, 2024 | 2.002B |
| Date | Value |
|---|---|
| October 16, 2024 | 2.015B |
| October 15, 2024 | 1.989B |
| October 14, 2024 | 1.972B |
| October 11, 2024 | 1.963B |
| October 10, 2024 | 1.928B |
| October 09, 2024 | 1.958B |
| October 08, 2024 | 1.973B |
| October 07, 2024 | 2.030B |
| October 04, 2024 | 2.096B |
| October 03, 2024 | 2.033B |
| October 02, 2024 | 2.011B |
| October 01, 2024 | 2.027B |
| September 30, 2024 | 1.993B |
| September 27, 2024 | 1.514B |
| September 26, 2024 | 1.520B |
| September 25, 2024 | 1.486B |
| September 24, 2024 | 1.499B |
| September 23, 2024 | 1.512B |
| September 20, 2024 | 1.540B |
| September 19, 2024 | 1.535B |
| September 18, 2024 | 1.530B |
| September 17, 2024 | 1.485B |
| September 16, 2024 | 1.477B |
| September 13, 2024 | 1.489B |
| September 12, 2024 | 1.458B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
317.39M
Minimum
Mar 18 2020
2.096B
Maximum
Oct 04 2024
1.082B
Average
1.167B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 198.27B |
| Context Therapeutics Inc | 37.45M |
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 9.335M |
| Revenue (Quarterly) | 159.30M |
| Total Expenses (Quarterly) | 124.46M |
| EPS Diluted (Quarterly) | 0.27 |
| Gross Profit Margin (Quarterly) | 60.76% |
| Profit Margin (Quarterly) | 5.86% |
| Earnings Yield | 7.66% |
| Operating Earnings Yield | 13.86% |
| Normalized Earnings Yield | 8.263 |